Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third-dose MMR vaccine immunogenicity and safety study in healthy young adults
NL-OMON47906Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of measles, mumps, and rubella vaccine in mumps, measles and rubella, sponsored by National Institute for Public Health and the Environment. Primary endpoints: Mumps-specific virus neutralization antibody concentrations at 3 years and Mumps-specific IgG antibody concentrations and avidity at 3 years. Started Oct 2016; status: completed.
02
Drugs
measles, mumps, and rubella vaccine
03
Conditions
mumpsmeaslesrubella
Beyond the preview
Go deeper on NL-OMON47906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47906.